Search Results for ""

“Estrogen plays a key role in promoting the proliferation of normal and breast cancer epithelium. So now we have gone from focusing just on the estrogen to also look at estrogen receptors on breast cancer cells and targeting that—and now even to a point of looking at the downstream effects of when the estrogen binds to estrogen receptor of those signaling pathways,” Rowena “Moe” Schwartz, PharmD, BCOP, FHOPA, professor of pharmacy practice at James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about estrogen-targeting anticancer therapies. 

“I think the reality is that we as humans are having a human experience, some of which is incredible and some of which is terrible. And to deny ourselves the opportunity to feel any of those emotions would be to deny our own human experience. And so processing feelings, and I think the bigger ones in particular, like grief, especially in the work that we do, it’s not only good to do, but it’s part of just what it means to, I think, be a human,” Ann Konkoly, MBA, MSN, APRN-CNM, chief executive officer of Authentic Koaching LLC and Kultivate Women’s Health LLC, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about processing grief in a healthcare context.

“I think poor discharge planning is that top contributor [to readmission]. And by that, I mean discharge planning that doesn’t assess a patient’s educational level, their support at home, what resources they have, like transportation and finances, and then to go further, evaluating if the patient even understand the reason they were admitted and then how to manage their care once they leave. There’s only so much we can treat in the hospital. what happens at home is what we need to prepare our patients for,” Stephanie Frost, MN, RN, OCN®, manager of outpatient clinics at City of Hope Cancer Center Chicago in Illinois, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about preventing hospital readmissions in patients with cancer.

“One of the things that I know Dr. [Tom] Connor worked on very heavily in his career is the long-term impact on the health of nurses and other exposed healthcare workers. We definitely need more longitudinal studies, which are difficult to do. And it’s not something that you see every day where I talk to chemo nurses and said, ‘Hey, I’ve been in this 20 years. It hasn't bothered me at all.’ Well, until it does. Therefore, it’s so important when we’re training incoming nurses—how very important it is to start with these practices early in the career and throughout the career,” Charlotte A. Smith, RPh, MS, senior regulatory advisor at Waste Management PharmEcology Services in Milwaukee, WI, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about hazardous drug and waste disposal.

“Chemotherapy exposure during the first trimester is contraindicated and increases the risk of spontaneous abortion, fetal death, and major congenital malformations. Second- and third-trimester exposure may affect some body systems still developing and can still result in fetal growth restriction, low birth weight, and preterm labor. Yet, you want to stress that pregnancy can remain a possibility,” Kelsey Miller, MSN, RN, AGCNS-BC, OCN®, clinical nurse specialist in oncology and infusion therapy at Reading Hospital in West Reading, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about policies and procedures for pregnancy testing during cancer treatment.

“I can't stress enough how often I get questions about, ‘Is this the paclitaxel doing this? Is this the docetaxel doing this?’ And coming up with strategies to kind of help get our patients through with supportive care is important. It's a really big opportunity for pharmacists and our nurses to really provide it and help our patients get through and show the knowledge that we have and to help them,” Dane Fritzsche, PharmD, BCOP, oncology informatics pharmacist at the Fred Hutchinson Cancer Center and University of Washington Medicine in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about the plant alkaloid drug class.

“Let’s take time, invest time, in learning more about futility. Let’s invest some time in learning more about how to understand our patient’s goals, their family’s goals, what their values are,” Kathleen Turner, BSN, RN, CHPN, CCRN-CMC, clinical nurse in the medical-surgical intensive care unit at the University of California, San Francisco, Medical Center, told Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, during a discussion on a nurse’s approach to futility in cancer care and treatment.

“It’s not often in life that you find something that gives you this feeling, but I’m really so fortunate to have found mine, and I know this is only just the beginning, and I cannot wait to see what the future holds. I definitely owe a lot of that to the Oncology Nursing Society for opening up all those doors for me and really getting me into this field.” Samantha Paulen, BSN, RN, told Jessica MacIntyre, DNP, MBA, APRN, AOCNP®, 2024–2026 ONS president, during a conversation about student nurses entering the oncology field. MacIntyre spoke with Paulen and Tayler Covino, BSN, RN, both recent graduate nurses, about why they chose oncology nursing as a specialty.

“Trying to give them as much autonomy as possible is really important. I always like to ask, ‘Would you like to have a conversation? Do you think that you can handle a conversation about advance care planning?’ Or ‘What you would want someone to do for you if you're not able to speak for yourself?’ They may say no, you know, and we have to respect that too,” Mandi Zucker, LSW, CT, executive director of End of Life Choices New York in New York City, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about end-of-life and advance care planning for adolescents and young adults with cancer.

“A couple of things I think are really important when you look at this class of drug: It developed by a concerted effort in cancer drug development to look at new agents that would be effective based on the mechanism. And then once they found a drug in this class that was beneficial, they further modified it to try to get better efficacy and less toxicity,” Rowena “Moe” Schwartz, PharmD, BCOP, FHOPA, professor of pharmacy practice at James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the nitrosoureas drug class.